[ CAS No. 4965-34-8 ] {[proInfo.proName]}

Name: 4965-34-8|7-Bromo-2-methylquinoline|97%
Brand: Ambeed
SKU: A231279
Price: 17.0 USD
Availability: InStock
Rating: 94 (29 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 4965-34-8

Structure of 4965-34-8 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 4965-34-8 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 4965-34-8 ]

SDS Specification

Alternatived Products of [ 4965-34-8 ]

Product Details of [ 4965-34-8 ]

CAS No. :	4965-34-8	MDL No. :	MFCD09787847
Formula :	C₁₀H₈BrN	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	VEKOCCXFMXGRTF-UHFFFAOYSA-N
M.W :	222.08	Pubchem ID :	12332896
Synonyms :

Calculated chemistry of [ 4965-34-8 ]

Physicochemical Properties

Num. heavy atoms :	12
Num. arom. heavy atoms :	10
Fraction Csp3 :	0.1
Num. rotatable bonds :	0
Num. H-bond acceptors :	1.0
Num. H-bond donors :	0.0
Molar Refractivity :	54.41
TPSA :	12.89 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	Yes
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.33 cm/s

Lipophilicity

Log Po/w (iLOGP) :	2.39
Log Po/w (XLOGP3) :	3.28
Log Po/w (WLOGP) :	3.31
Log Po/w (MLOGP) :	2.85
Log Po/w (SILICOS-IT) :	3.6
Consensus Log Po/w :	3.08

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-3.9
Solubility :	0.028 mg/ml ; 0.000126 mol/l
Class :	Soluble
Log S (Ali) :	-3.23
Solubility :	0.132 mg/ml ; 0.000595 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-4.95
Solubility :	0.00251 mg/ml ; 0.0000113 mol/l
Class :	Moderately soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.46

Safety of [ 4965-34-8 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 4965-34-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 4965-34-8 ]
Downstream synthetic route of [ 4965-34-8 ]

[ 4965-34-8 ] Synthesis Path-Upstream 1~7

1
[ 591-19-5 ]
[ 123-63-7 ]
[ 4965-34-8 ]

Yield	Reaction Conditions	Operation in experiment
46%	Stage #1: With hydrogenchloride In water at 0 - 20℃; for 4 h; Reflux Stage #2: With sodium hydroxide In water at 0℃;	Doebner Miller synthesis: 3-Bromoaniline (10 mL, 92 mmol) was added to a solution of 37 percent HCl at 0 °C (200 mL). Paraldehyde (11 mL, 0.8 mol, 9 eq) was then introduced and the mixture was left to react at room temperature for 1 hour, and then heated to reflux temperature for 3 hours. After cooling to 0 °C, a saturated aquous solution of sodium hydroxide (200 mL) was slowly added and the mixture was extracted with dichloromethane. The organic layer was washed with water and brine, then dried over MgSO₄, and concentrated under reduced pressure. The crude product was obtained as a mixture of 5-bromoquinaldine and 7-bromoquinaldine that were separated by column chromatography (SiO₂, cyclohexane-AcOEt 9:1). The 7-bromoquinaldine regioisomer was obtained as a sand yellow solid (9,3 g, 46 percent). Molecular formula: C₁₀H₈BrN. Molecular weight: 222.08 g.mol^-1. IR (film): 1610, 1494, 1264, 841, 736 cm^-1. T_fusion: 57 °C. ¹H NMR: δ 8.09 (s, 1H, H₈), 7.80 (d, J = 8.2 Hz, 1H, H₄), 7.39 (m, 2H, H₅ et H₇), 7.12 (d, J = 8.2 Hz, 1H, H₃), 2.61 (s, 3H, H₉). ¹³C NMR: δ 160.3 (s, C₂), 148.6 (s, C_8a), 136.2 (s, C₄), 131.2 (s, C₈), 129.4 (s, C₅), 128.9 (s, C₆), 125.3 (s, C_4a), 123.7 (s, C₇), 122.6 (s, C₃), 25.7 (s, C₉).

Reference： [1] Patent: EP2397466, 2011, A1, . Location in patent: Page/Page column 12
[2] Angewandte Chemie - International Edition, 2011, vol. 50, # 41, p. 9708 - 9711
[3] Journal of the American Chemical Society, 1921, vol. 43, p. 2257
[4] Chemical and Pharmaceutical Bulletin, 1981, vol. 29, # 6, p. 1615 - 1623

2
[ 50-00-0 ]
[ 591-19-5 ]
[ 4965-34-8 ]

Yield	Reaction Conditions	Operation in experiment
46%	Stage #1: With hydrogenchloride In water at 0℃; for 4 h; Reflux Stage #2: With sodium hydroxide In water at 0℃;	1) Preparation of 7-bromo-2-methyl-quinolineDoebner-Miller synthesis:3-bromoaniline (3 mL, 27 mmol), was added to a solution of 37percent HC1 at 0°C (24 mL). Paraldehyde (8 mL, 83 mmol, 3 eq) was then introduced and the mixture was left to react at room temperature for 1 hour, then refluxed for 3 hours. After cooling to 0°C, sodium hydroxide (25 mL) was added dropwise and the mixture was extracted with dichloromethane. The organic layer was washed twice with water and brine, then dried over MgS0₄, and concentrated under reduced pressure. The product was purified by column chromatography (Si0₂, Cyclohexane-AcOEt 9/1) and obtained as a white solid (2.8 g, 46percent).Molecular formula: Ci₀HgBrNMolecular weight: 222.08 g.mol^"1 IR (film): 1610, 1494, 1264, 841, 736 cm^-1 Melting point: 57°C1H NMR: 8), 7.80 (d, J = 8.2 Hz, 1H, 3/4), 7.39 (m, 2H, H₅ and H₇), 7.12 (d, J= 8.2 Hz, 1H, H₃), 2.61 (s, 3H, H₉).1³C NMR: δ 160.3 (s, C₂), 148.6 (s, C_8a), 136.2 (s, C₄), 131.2 (s, C₈), 129.4 (s, C₅), 128.9 (s, C₆), 125.3 (s, C_4a), 123.7 (s, C₇), 122.6 (s, C₃), 25.7 (s, C₉).R_f= 0.33 (Cyclohexane/EtOAc: 2/1), 0.73 (Cyclohexane/EtOAc: 1/1).

Reference： [1] Patent: WO2011/86469, 2011, A1, . Location in patent: Page/Page column 32

3
[ 591-19-5 ]
[ 123-63-7 ]
[ 4965-34-8 ]
[ 54408-52-5 ]

Yield	Reaction Conditions	Operation in experiment
46%	Stage #1: With hydrogenchloride In water at 0℃; for 4 h; Reflux Stage #2: With sodium hydroxide In water at 0℃;	3-Bromoaniline (10 mL, 92 mmol) was added to a solution of 37 percent HC1 at 0 °C (200 mL). Paraldehyde (1 1 mL, 0.8 mol, 9 eq) was then introduced and the mixture was left to react at room temperature for 1 hour, and then heated to reflux temperature for 3 hours. After cooling to 0 °C, a saturated aquous solution of sodium hydroxide (200 mL) was slowly added and the mixture was extracted with dichloromethane. The organic layer was washed with water and brine, then dried over MgS0₄, and concentrated under reduced pressure. The crude product was obtained as a mixture of 5-bromoquinaldine and 7-bromoquinaldine that were separated by column chromatography (Si0₂, cyclohexane- AcOEt 9: 1). The 7-bromoquinaldine regioisomer was obtained as a sand yellow solid (9,3 g, 46 percent).Molecular formula: CioH8BrN.Molecular weight: 222.08 g.mol^"s.IR (film): 1610, 1494, 1264, 841, 736 cm^"1.T_fusion: 57 °C.1H NMR: δ 8.09 (s, 1H, H₈), 7.80 (d, J = 8.2 Hz, 1H, H₄), 7.39 (m, 2H, H₅ et H₇), 7.12 (d, J= 8.2 Hz, 1H, H₃), 2.61 (s, 3H, H₉).¹³C NMR: δ 160.3 (s, C₂), 148.6 (s, C_8a), 136.2 (s, C₄), 131.2 (s, C₈), 129.4 (s, C₅), 128.9(s, C₆), 125.3 (s, C_4a), 123.7 (s, C₇), 122.6 (s, C₃), 25.7 (s, C₉).

Reference： [1] Patent: WO2011/158189, 2011, A1, . Location in patent: Page/Page column 14-15

4
[ 123-73-9 ]
[ 591-19-5 ]
[ 4965-34-8 ]

Reference： [1] Tetrahedron Letters, 2006, vol. 47, # 11, p. 1783 - 1785

5
[ 70557-29-8 ]
[ 4965-34-8 ]

Reference： [1] Organic and Biomolecular Chemistry, 2017, vol. 15, # 30, p. 6349 - 6352

6
[ 5551-12-2 ]
[ 4965-34-8 ]

Reference： [1] Organic and Biomolecular Chemistry, 2017, vol. 15, # 30, p. 6349 - 6352

7
[ 4965-34-8 ]
[ 19490-87-0 ]

Reference： [1] Chemical and Pharmaceutical Bulletin, 1981, vol. 29, # 6, p. 1615 - 1623

[ 4965-34-8 ] Synthesis Path-Downstream 1~56

1
[ 591-19-5 ]
[ 123-63-7 ]
[ 4965-34-8 ]

Yield	Reaction Conditions	Operation in experiment
46%		Doebner Miller synthesis: 3-Bromoaniline (10 mL, 92 mmol) was added to a solution of 37 % HCl at 0 C (200 mL). Paraldehyde (11 mL, 0.8 mol, 9 eq) was then introduced and the mixture was left to react at room temperature for 1 hour, and then heated to reflux temperature for 3 hours. After cooling to 0 C, a saturated aquous solution of sodium hydroxide (200 mL) was slowly added and the mixture was extracted with dichloromethane. The organic layer was washed with water and brine, then dried over MgSO4, and concentrated under reduced pressure. The crude product was obtained as a mixture of 5-bromoquinaldine and 7-bromoquinaldine that were separated by column chromatography (SiO2, cyclohexane-AcOEt 9:1). The 7-bromoquinaldine regioisomer was obtained as a sand yellow solid (9,3 g, 46 %). Molecular formula: C10H8BrN. Molecular weight: 222.08 g.mol-1. IR (film): 1610, 1494, 1264, 841, 736 cm-1. Tfusion: 57 C. 1H NMR: delta 8.09 (s, 1H, H8), 7.80 (d, J = 8.2 Hz, 1H, H4), 7.39 (m, 2H, H5 et H7), 7.12 (d, J = 8.2 Hz, 1H, H3), 2.61 (s, 3H, H9). 13C NMR: delta 160.3 (s, C2), 148.6 (s, C8a), 136.2 (s, C4), 131.2 (s, C8), 129.4 (s, C5), 128.9 (s, C6), 125.3 (s, C4a), 123.7 (s, C7), 122.6 (s, C3), 25.7 (s, C9).

Reference： [1]Patent: EP2397466,2011,A1 .Location in patent: Page/Page column 12
[2]Angewandte Chemie - International Edition,2011,vol. 50,p. 9708 - 9711
[3]Journal of the American Chemical Society,1921,vol. 43,p. 2257
[4]Chemical and Pharmaceutical Bulletin,1981,vol. 29,p. 1615 - 1623

2
[ 4965-34-8 ]
[ 108-24-7 ]
[ 100-83-4 ]
[ 108166-09-2 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 3832 - 3844

3
[ 4965-34-8 ]
[ 19490-87-0 ]

Reference： [1]Chemical and Pharmaceutical Bulletin,1981,vol. 29,p. 1615 - 1623

4
[ 29943-42-8 ]
[ 4965-34-8 ]
[ 192933-08-7 ]

Reference： [1]Journal of Medicinal Chemistry,1997,vol. 40,p. 2866 - 2875

5
[ 4965-34-8 ]
[ 108216-90-6 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 965 - 970

7
[ 123-73-9 ]
[ 591-19-5 ]
[ 4965-34-8 ]

Reference： [1]Tetrahedron Letters,2006,vol. 47,p. 1783 - 1785

8
[ 4965-34-8 ]
[ 168083-22-5 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 965 - 970

9
[ 4965-34-8 ]
4-[3-(7-bromo-2-quinolinylmethoxy)phenylamino]-2,2-diethyl-4-oxobutanoic acid [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 965 - 970

10
[ 4965-34-8 ]
[ 192933-01-0 ]

Reference： [1]Journal of Medicinal Chemistry,1997,vol. 40,p. 2866 - 2875

11
[ 4965-34-8 ]
2-cyano-4-(3-furyl)-7-({7-[4-(4-hydroxytetrahydropyranyl)]-2-quinolinyl}methoxy)naphthalene [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1997,vol. 40,p. 2866 - 2875

12
[ 4965-34-8 ]
[ 108193-13-1 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 3832 - 3844

13
[ 4965-34-8 ]
[ 143816-70-0 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 3832 - 3844

14
[ 4965-34-8 ]
[ 108177-35-1 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 3832 - 3844

15
[ 4965-34-8 ]
[ 108165-87-3 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 3832 - 3844

16
[ 4965-34-8 ]
[ 42835-97-2 ]

Reference： [1]Chemical and Pharmaceutical Bulletin,1981,vol. 29,p. 1615 - 1623
[2]Chemical and Pharmaceutical Bulletin,1981,vol. 29,p. 1615 - 1623

17
[ 4965-34-8 ]
[ 79217-08-6 ]

Reference： [1]Chemical and Pharmaceutical Bulletin,1981,vol. 29,p. 1615 - 1623
[2]Chemical and Pharmaceutical Bulletin,1981,vol. 29,p. 1615 - 1623
[3]Chemical and Pharmaceutical Bulletin,1981,vol. 29,p. 1615 - 1623
[4]Chemical and Pharmaceutical Bulletin,1981,vol. 29,p. 1615 - 1623

18
[ 4965-34-8 ]
2-methyl-7-bromo-quinoline-1-oxide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With 3-chloro-benzenecarboperoxoic acid; In hexane; dichloromethane;	(a) <strong>[4965-34-8]2-methyl-7-bromo-quinoline</strong>-1-oxide A solution of 10.05 g of m-chloroperbenzoic acid in 75 ml of CH2 Cl2 is added dropwise at 0-10 in the course of 30 min. to a solution of 7.09 g of <strong>[4965-34-8]2-methyl-7-bromo-quinoline</strong> [C. M. Leir, J. Org. Chem. 42(5) (1977) 911-913] in 75 ml of n-hexane and then the batch is stirred for 16 hours at 20. It is then diluted with ethyl acetate, washed in succession with 2N aqueous solutions of K2 CO3, Na2 S2 O3 and NaCl, dried over Na2 SO4 and concentrated by evaporation to give the title compound which is purified by crystallisation from CH2 Cl2 /ether/hexane.

Reference： [1]Patent: US5508408,1996,A

19
[ 4965-34-8 ]
3-(2-(7-bromoquinolin-2-yl)ethenyl)benzaldehyde [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With acetic anhydride;	Step 1: Preparation of 3-(2-(7-bromoquinolin-2- yl)ethenyl)benzaldehyde A suspension of isophtaldehyde (10 g), <strong>[4965-34-8]7-bromoquinaldine</strong> (16.6 g) and acetic anhydride (75 ml) was heated at 125 for 48 hours. The reaction mixture was cooled, diluted with ether (100 ml) and filtered to give the title compound which was used as is for the next step.

Reference： [1]Patent: EP219307,1987,A3

20
[ 4965-34-8 ]
[ 124-38-9 ]
[ 1315571-48-2 ]

Yield	Reaction Conditions	Operation in experiment
		Intermediate 1 : Lithium 2-methyl-7-quinolinecarboxylateTo a solution of <strong>[4965-34-8]7-bromo-2-methylquinoline</strong> (400 mg, supplier Bioblocks Inc.) in THF (8 mL) under argon at -78 C was added n-butyllithium (0.865 mL) dropwise. The reaction was stirred for 15 minutes at -78 C before it was poured onto solid carbon dioxide in a beaker. The mixture was swirled until warmed to room temperature to prevent bumping, then the solvent was removed in vacuo to give the crude title compound (404 mg), which was used directly in subsequent reactions.LCMS (low pH) RT 0.36 min, m/z (ES) 188 [M+H]+
		Intermediate 1: Lithium 2-methyl-7-quinolinecarboxylate[0171][0172]To a solution of <strong>[4965-34-8]7-bromo-2-methylquinoline</strong> (400 mg, supplier Bioblocks Inc.) in THF (8 mL) under argon at -78 C. was added n-butyllithium (0.865 mL) dropwise. The reaction was stirred for 15 minutes at -78 C. before it was poured onto solid carbon dioxide in a beaker. The mixture was swirled until warmed to room temperature to prevent bumping, then the solvent was removed in vacuo to give the crude title compound (404 mg), which was used directly in subsequent reactions.[0173]LCMS (low pH) RT 0.36 min, m/z (ES) 188 [M+H]+

Reference： [1]Patent: WO2011/86377,2011,A1 .Location in patent: Page/Page column 24-25
[2]Patent: US2013/72499,2013,A1 .Location in patent: Paragraph 0170-0173

21
[ 50-00-0 ]
[ 591-19-5 ]
[ 4965-34-8 ]

Yield	Reaction Conditions	Operation in experiment
46%		1) Preparation of 7-bromo-2-methyl-quinolineDoebner-Miller synthesis:3-bromoaniline (3 mL, 27 mmol), was added to a solution of 37% HC1 at 0C (24 mL). Paraldehyde (8 mL, 83 mmol, 3 eq) was then introduced and the mixture was left to react at room temperature for 1 hour, then refluxed for 3 hours. After cooling to 0C, sodium hydroxide (25 mL) was added dropwise and the mixture was extracted with dichloromethane. The organic layer was washed twice with water and brine, then dried over MgS04, and concentrated under reduced pressure. The product was purified by column chromatography (Si02, Cyclohexane-AcOEt 9/1) and obtained as a white solid (2.8 g, 46%).Molecular formula: Ci0HgBrNMolecular weight: 222.08 g.mol"1 IR (film): 1610, 1494, 1264, 841, 736 cm-1 Melting point: 57C1H NMR: <S 8.09 (s, 1H, H8), 7.80 (d, J = 8.2 Hz, 1H, ¾), 7.39 (m, 2H, H5 and H7), 7.12 (d, J= 8.2 Hz, 1H, H3), 2.61 (s, 3H, H9).13C NMR: delta 160.3 (s, C2), 148.6 (s, C8a), 136.2 (s, C4), 131.2 (s, C8), 129.4 (s, C5), 128.9 (s, C6), 125.3 (s, C4a), 123.7 (s, C7), 122.6 (s, C3), 25.7 (s, C9).Rf= 0.33 (Cyclohexane/EtOAc: 2/1), 0.73 (Cyclohexane/EtOAc: 1/1).

Reference： [1]Patent: WO2011/86469,2011,A1 .Location in patent: Page/Page column 32

22
[ 4965-34-8 ]
[ 1066-54-2 ]
[ 1315248-50-0 ]

Yield	Reaction Conditions	Operation in experiment
81%	With copper(l) iodide; diethylamine; triphenylphosphine;bis-triphenylphosphine-palladium(II) chloride; In N,N-dimethyl-formamide; at 110℃;Sealed tube;	3) Preparation of 2-methyl-7-trimethyIsilanylethynyl-quinoline:In a sealed tube were introduced <strong>[4965-34-8]7-bromo-2-methyl-quinoline</strong> (500 mg, 2.25 mmol, 1.0 eq), PdCl2(PPh3)3 (79 mg, 0.1 1 mmol, 5% mol), copper iodide (21 mg, 0.11 mmol, 5% mol), and triphenylphosphine (106 mg, 0.39 mmol, 20% mol). Then, DMF (5 mL) was added followed by diethylamine (3.5 mL, 34 mmol, 15 eq) and trimethylsilylacetylene (350 mu,, 2.5 mmol, 1.1 eq). The mixture was heated at 1 10 C overnight. After cooling down the solvent was evaporated and the crude product was purified by column chromatography (Florisil, Cyclohexane-EtOAc 95:5) to afford 2- methyl-7-trimethylsilanylethynyl-quinoline as a white solid (435 mg, 81%).Molecular formula: C15H17NS1Molecular weight: 239.39 g.mol"1 Rf= 0.34 (Cyclohexane EtOAc: 95/5).Mp: 96 C. NMR (250 MHz): 8.15 (s, 1H, H8), 8.00 (d, J= 8.2 Hz, 1H, H4), 7.69 (d, J= 8.2 Hz, 1H, H5), 7.52 (d, J = 8.2 Hz, 1H, H6), 7.28 (d, J = 8.2 Hz, 1H, H3), 2.75 (s, 3H, H9), 0.30 (s, 9H, TMS).,3C NMR (63 MHz): £ 160.1 (s, C2), 147.8 (s, C8a), 136.1 (s, C4), 132.8 (s, C8), 128.9 (s, C6), 127.8 (s, C5), 126.7 (s, C4a), 124.5 (s, C7), 122.9 (s, H3), 105.2 (s, C10), 96.5 (s, Cn), 25.8 (s, C9), 0.40 (s, TMS).

Reference： [1]Patent: WO2011/86469,2011,A1 .Location in patent: Page/Page column 38-39

23
[ 4965-34-8 ]
[ 904369-20-6 ]

Yield	Reaction Conditions	Operation in experiment
> 98%	With selenium(IV) oxide; In 1,4-dioxane; at 60 - 80℃; for 3.0h;	2) Preparation of 7-bromo-quinoline-2-carbaldehydeSelenium dioxyde (1.6 g, 14 mmol, 1.3 eq) in suspension in dioxane (50 mL) was heated at 60C. <strong>[4965-34-8]7-bromoquinaldine</strong> (2.5 g, 1 1.2 mmol) was the introduced and the mixture was left to react at 80C for 3 hours. After cooling to room temperature, the mixture was filtered on celite, eluted with dioxane and concentrated under reduced pressure. The product was obtained pure as a white solid (3.3 g, > 98%).Molecular formula: Ci0H6BrNO Molecular weight: 236.06 g.mol" IR (film): 1701, 1587, 1298, 91 1, 843, 757 cm"1 Melting point: 151CSM-IC+ (CH3OH) m/z: 236 (M+H+), 268 (hemiacetal), 282 (acetal).MS (ESI): m/z = 236.0, 238.0 [M+H]+, 258.0, 260.0 [M+Na]+, 268.0, 270.0 (hemiacetal), 282.0, 284.0 (acetal).HRMS (ESI): m/z calculated for [Ci0H6BrNO+H]+ 235.971 1, found 235.9702 (ppm -3.8); 237.9691, found 237.9681 (ppm -4.0).
	With selenium(IV) oxide; In 1,4-dioxane; at 60 - 80℃; for 3.0h;Product distribution / selectivity;	7-Bromoquinoline-2-carbaldehyde synthesis: Selenium dioxide (1.6 g, 14 mmol, 1.3 eq) was suspended in dioxan (50 mL) and was heated to 60 C. At this temperature <strong>[4965-34-8]7-bromoquinaldine</strong> (2.5 g, 11.2 mmol) was introduced and the mixture was left at 80 C for 3 hours. After cooling the mixture to room temperature, the crude slurry was filtered on celite, eluted with dioxan and concentrated under reduced pressure. The product was obtained pure as a brown solid (3.3 g, > 98 %) that was used without furter purification. Molecular formula: C10H6BrNO. Molecular weight: 236.06 g.mol-1. IR (film): 1701, 1587, 1298, 911, 843, 757 cm-1. Tfusion: 151 C. SM-IC+ (CH3OH) m/z: 236 (M + H+), 268 (hmiacetal), 282 (acetal).
	With selenium(IV) oxide; In 1,4-dioxane; at 60 - 80℃; for 3.0h;	Selenium dioxide (1.6 g, 14 mmol, 1.3 eq) was suspended in dioxan (50 mL) and was heated to 60 C. At this temperature <strong>[4965-34-8]7-bromoquinaldine</strong> (2.5 g, 11.2 mmol) was introduced and the mixture was left at 80 C for 3 hours. After cooling the mixture to room temperature, the crude slurry was filtered on celite, eluted with dioxan and concentrated under reduced pressure. The product was obtained pure as a brown solid(3.3 g, > 98 %) that was used without furter purification.Molecular formula: C] 0H6BrNO.Molecular weight: 236.06 g.mol'1.IR (film): 1701, 1587, 1298, 91 1 , 843, 757 cm"1.Tfusion- 151 C.SM-IC+ (CH3OH) m/z: 236 (M + H+), 268 (hemiacetal), 282 (acetal).

Reference： [1]Patent: WO2011/86469,2011,A1 .Location in patent: Page/Page column 32-33
[2]Angewandte Chemie - International Edition,2011,vol. 50,p. 9708 - 9711
[3]ChemistryOpen,2017,vol. 6,p. 660 - 667
[4]Patent: EP2397466,2011,A1 .Location in patent: Page/Page column 12
[5]Patent: WO2011/158189,2011,A1 .Location in patent: Page/Page column 15

24
[ 4965-34-8 ]
[ 1267481-50-4 ]

Reference： [1]Patent: WO2011/86469,2011,A1
[2]Angewandte Chemie - International Edition,2011,vol. 50,p. 9708 - 9711
[3]Patent: EP2397466,2011,A1
[4]Patent: WO2011/158189,2011,A1
[5]ChemistryOpen,2017,vol. 6,p. 660 - 667

25
[ 4965-34-8 ]
[ 64334-96-9 ]

Yield	Reaction Conditions	Operation in experiment
90%	With copper(l) iodide; ammonia; potassium carbonate; L-proline; In water; dimethyl sulfoxide; at 80℃; for 18.0h;	4) Preparation of 2-methyl-quinolin-7-ylamine The 7-bromoquinoline derivative (800 mg, 3.6 mmol, 1 eq), copper iodide (137 mg, 0.7 mmol, 20 mol%), L-proline (166 mg, 1.4 mmol, 40 mol%) and K2C03 (1.5 g, 1 1 mmol, 3 eq) were dissolved in DMSO (20 niL). Aqueous ammonia 28% NH4OH (2 mL) was then introduced and the mixture was heated at 80C for 18 hours. After cooling to room temperature, dichloromethane was added followed by a saturated NH4C1 solution. The aqueous layer was extracted twice with dichloromethane, and the combined organic layers were washed again with a saturated NH4C1 solution. The product was purified by column chromatography (Si02, Cyclohexane-AcOEt 1/3) and obtained as a white powder(511 mg, 90%).Molecular formula : C 10H 10N2 Molecular weight: 158.20 g.mol"1 NMR (500 MHz): 7.69 (d, J = 8.0 Hz, 1H, H4), 7.38 (d, J= 8.5 Hz, 1H, H5), 7.04 (s, 1H, H8), 7.85 (d, J = 8.0 Hz, 1H, H3), 6.77 (d, J = 8.5 Hz, 1H, H6), 4.26 (bb, 2H, NH2),2.58 (s, 3H, H9).13C NMR (125 MHz): delta 160.3 (s, C2), 151.0 (s, C8a), 149.6 (s, C7), 137.1 (s, C4), 129.9 (s, C5), 121.5 (s, C4a), 1 19.6 (s, C4), 119.0 (s, C6), 109.8 (s, C8), 42.2 (s, C9).Rf= 0.20 (Dichloromethane/MeOH: 95/5).ESI m/z; 159.2 (M+H+).

Reference： [1]Organic Letters,2017,vol. 19,p. 2809 - 2812
[2]Patent: WO2011/86469,2011,A1 .Location in patent: Page/Page column 33-34

26
[ 4965-34-8 ]
[ 1315248-51-1 ]

Reference： [1]Patent: WO2011/86469,2011,A1

27
[ 64334-96-9 ]
[ 4965-34-8 ]
[ 1315248-47-5 ]

Yield	Reaction Conditions	Operation in experiment
65%	With tri-tert-butyl phosphine; sodium t-butanolate;tris-(dibenzylideneacetone)dipalladium(0); In toluene; at 110℃; for 18.0h;Sealed tube;	5) Preparation of tris-(2-methyl-quinoIin-7-yl)-amineIn a sealed tube placed in the glove box, the 6-aminoquinoline derivative (400 mg, 2.5 mmol, 1 eq), the 6-bromoquinoline derivative (1.2 g, 5.4 mmol, 2.2 eq), Pd2dba3 (259 mg, 0.25 mmol, 10 mol%) and sodium tertbutoxide NaOC(CH3)3 (577 mg, 6.0 mmol, 2.4 eq) were introduced. 1 M in toluene solution of tritertbutylphosphine PlBu3 (106 mu,, 0.5 mmol, 20 mol%) and distilled toluene (12 mL) were added and the tube was sealed. The mixture was heated at 1 10C for 18 hours. After cooling to room temperature, the solvent was removed under reduced pressure, then dichloromethane was added and the organic layer was washed twice with water and brine. The product was purified by column chromatography (Si02, Dichloromethane-MeOH 99/1) and. obtained as a yellow powder (715 mg, 65%).Molecular formula: C30H24N4 Molecular weight: 440.54 g.mol"1 1H NMR (250 MHz): delta 7.93 (d, J = 8.3 Hz, 1H, H4), 7.68 (d, J = 8.5 Hz, 1H, H5), 7.66 (d, J= 2.5 Hz, 1H, H8), 7.40 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H, H6), 7.15 (d, J = 8.3 Hz, 1H, H3), 2.63 (s, 3H, H9).13C NMR (125 MHz): delta 159.8 (s, C2), 149.4 (s, C8a), 148.6 (s, C7), 136.0 (s, C4), 129.0 (s, C5), 124.4 (s, C6), 123.9 (s, C4a), 122.5 (s, C3), 121.2 (s, C8), 25.6 (s, C9).Rf= 0.36 (Dichloromethane/MeOH: 95/5).ESI m/z: 441 (M+H+), 881 (2M+H+).

Reference： [1]Patent: WO2011/86469,2011,A1 .Location in patent: Page/Page column 34-35

28
[ 4965-34-8 ]
[ 1352204-62-6 ]

Reference： [1]Angewandte Chemie - International Edition,2011,vol. 50,p. 9708 - 9711

29
[ 4965-34-8 ]
[ 1352204-65-9 ]

Reference： [1]Angewandte Chemie - International Edition,2011,vol. 50,p. 9708 - 9711
[2]Patent: EP2397466,2011,A1
[3]Patent: WO2011/158189,2011,A1
[4]ChemistryOpen,2017,vol. 6,p. 660 - 667

30
[ 4965-34-8 ]
[ 1352204-68-2 ]

Reference： [1]Angewandte Chemie - International Edition,2011,vol. 50,p. 9708 - 9711
[2]Patent: EP2397466,2011,A1
[3]Patent: WO2011/158189,2011,A1

31
[ 4965-34-8 ]
[ 1352640-57-3 ]

Reference： [1]Angewandte Chemie - International Edition,2011,vol. 50,p. 9708 - 9711

32
[ 4965-34-8 ]
[ 1352204-61-5 ]

Reference： [1]Angewandte Chemie - International Edition,2011,vol. 50,p. 9708 - 9711

33
[ 4965-34-8 ]
5-[4-(2-Hydroxymethyl-quinolin-7-yl)-piperazin-1-yl]-5-oxo-2-(4,7,10-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-pentanoic acid tert-butyl ester [ No CAS ]

Reference： [1]Patent: EP2397466,2011,A1
[2]Patent: WO2011/158189,2011,A1

34
[ 4965-34-8 ]
[4-(1-acetyl-4-[4-[2-(tert-butyl-dimethyl-silanyloxymethyl)-quinolin-7-yl]-piperazin-1-yl]-4-oxo-butyl)-10-butoxycarbonylmethyl-7-(2-oxo-propyl)-1,4,7,10-tetraaza-cyclododec-1-yl]-acetic acid butyl ester [ No CAS ]

Reference： [1]Patent: EP2397466,2011,A1
[2]Patent: WO2011/158189,2011,A1

35
[ 4965-34-8 ]
5-oxo-5-[4-[2-(3-phenyl-propionyloxymethyl)-quinolin-7-yl]-piperazin-1-yl]-2-(4,7,10-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-pentanoic acid tert-butyl ester [ No CAS ]

Reference： [1]Patent: EP2397466,2011,A1
[2]Patent: WO2011/158189,2011,A1

36
[ 591-19-5 ]
[ 123-63-7 ]
[ 4965-34-8 ]
[ 54408-52-5 ]

Yield	Reaction Conditions	Operation in experiment
46%		3-Bromoaniline (10 mL, 92 mmol) was added to a solution of 37 % HC1 at 0 C (200 mL). Paraldehyde (1 1 mL, 0.8 mol, 9 eq) was then introduced and the mixture was left to react at room temperature for 1 hour, and then heated to reflux temperature for 3 hours. After cooling to 0 C, a saturated aquous solution of sodium hydroxide (200 mL) was slowly added and the mixture was extracted with dichloromethane. The organic layer was washed with water and brine, then dried over MgS04, and concentrated under reduced pressure. The crude product was obtained as a mixture of 5-bromoquinaldine and 7-bromoquinaldine that were separated by column chromatography (Si02, cyclohexane- AcOEt 9: 1). The 7-bromoquinaldine regioisomer was obtained as a sand yellow solid (9,3 g, 46 %).Molecular formula: CioH8BrN.Molecular weight: 222.08 g.mol"s.IR (film): 1610, 1494, 1264, 841, 736 cm"1.Tfusion: 57 C.1H NMR: delta 8.09 (s, 1H, H8), 7.80 (d, J = 8.2 Hz, 1H, H4), 7.39 (m, 2H, H5 et H7), 7.12 (d, J= 8.2 Hz, 1H, H3), 2.61 (s, 3H, H9).13C NMR: delta 160.3 (s, C2), 148.6 (s, C8a), 136.2 (s, C4), 131.2 (s, C8), 129.4 (s, C5), 128.9(s, C6), 125.3 (s, C4a), 123.7 (s, C7), 122.6 (s, C3), 25.7 (s, C9).

Reference： [1]Patent: WO2011/158189,2011,A1 .Location in patent: Page/Page column 14-15

37
[ 4965-34-8 ]
C₄₂H₅₅N₇O₁₁ [ No CAS ]

Reference： [1]Patent: WO2011/158189,2011,A1

38
[ 4965-34-8 ]
[ 1426049-86-6 ]
(+)-2-(4-cyclopropyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)-2-(2-fluoro-4-(2-methylquinolin-7-yl)phenyl)acetamide [ No CAS ]
(-)-2-(4-cyclopropyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)-2-(2-fluoro-4-(2-methylquinolin-7-yl)phenyl)acetamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
21%; 21%		a) A solution of 2-(4-bromo-2-fluorophenyl)-2-(4-cyclopropyl-3-oxo-l-oxa-4,9- diazaspiro[5.5]undecan-9-yl)acetamide (0.341 mmol) in dry 1,4-dioxane (1.5 mL) was treated with bis(pinacolato)diboron (0.409 mmol), potassium acetate (0.499 mmol) and PdCl2(dppf)-CH2Cl2 adduct (0.017 mmol). The solution was degassed with a stream of nitrogen for three minutes, at which point the reaction vessel was purged with nitrogen and sealed, and the mixture stirred in an oil bath at 100 C overnight. At this point the reaction was cooled to room temperature and <strong>[4965-34-8]7-bromo-2-methylquinoline</strong> (0.341 mmol), PdCl2(dppf)-CH2Cl2 adduct (0.017 mmol), and 2M aq potassium carbonate (1.022 mmol) were added. The reaction vessel was purged with nitrogen and sealed, and the mixture irradiated in a Biotage Initiator Microwave at 120 C for 15 min. The resulting black mixture was diluted with water (100 mL) and brine (30 mL) and was extracted with ethyl acetate three times. The combined organic layers were treated with Silicycle Si-thiol (20 mg), dried over sodium sulfate, filtered and concentrated in vacuo. Purification of the residue by silica gel chromatography (0-9% methanol/dichloromethane) followed by chiral HPLC (Chromegachiral CC4, methanol) and lyophilization from water (w/ 25% acetonitrile) afforded the title compound as a white solid in >98%> ee (38 mg, 21%> yield). MS(ES)+ m/e 503.0 [M+H]+. aD = +48 deg (c = 0.04, methanol). Example 32 (-)-2-(4-cyclopropyl-3-oxo-l-oxa-4,9-diazaspiro[5.5]undecan-9-yl)-2-(2-fluoro-4-(2- methylquinolin-7-yl)phenyl)acetamide a) From Example 31a, the title product was isolated as a white solid in >98%> ee using chiral HPLC (Chromegachiral CC4, methanol) followed by lyophilization from water (w/ 25% acetonitrile) (38 mg, 21% yield). MS(ES)+ m/e 503.0 [M+H]+. aD = -27 deg (c = 0.04, methanol).

Reference： [1]Patent: WO2013/28447,2013,A1 .Location in patent: Page/Page column 88-89

39
[ 4965-34-8 ]
[ 74-88-4 ]
C₁₁H₁₁BrN⁽¹⁺⁾*I^(1-) [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In ethanol; for 15.0h;Reflux;	General procedure: Quinoline heterocycles were prepared according to the literature procedure [34]. Quaternary salts A were synthesized when a mixture of 0.016mmol quinoline heterocycles and 0.023mmol methyl iodide in ethanol was refluxed for 15h. After cooling, the product was filtered off and purified by recrystallization from EtOH. The dyes 1-13 were synthesized according to the literature [28,29]. The synthesis of dyes 14-20 followed the procedure [29] with slight modification. Various quaternary salts A (1mmol), aromatic aldehydes B (1mmol), 15mL anhydrous ethanol and a few drops of piperidine were mixed thoroughly together at ambient temperature in a dried round-bottom flask (50mL) equipped with a reflux condenser capped with an anhydrous CaCl2 drying tube. The mixture was subjected to microwave irradiation at appropriate time, power and temperature. After cooling, the crude products was filtered off and purified by two different methods depending on the dyes' solubility. For dyes 14-16, the crude products was recrystallized from EtOH-H2O to afford pure dyes. For dyes 17-20, having very poor solubility, the crude products was washed with diethyl ether and extracted with EtOH by Soxhlet extraction in 15h. The reaction details and yields of dyes 14-20 were listed in Table1.

Reference： [1]Dyes and Pigments,2014,vol. 100,p. 232 - 240

40
[ 4965-34-8 ]
7-bromo-2-methyl-8-nitroquinoline [ No CAS ]

Reference： [1]Organic Letters,2015,vol. 17,p. 402 - 405

41
[ 4965-34-8 ]
7-bromo-2-methylquinolin-8-amine [ No CAS ]

Reference： [1]Organic Letters,2015,vol. 17,p. 402 - 405

42
[ 4965-34-8 ]
[ 100-46-9 ]
(E)-7-bromo-2-styrylquinoline [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
90%	With lanthanum pentafluorobenzoate; In toluene; at 120℃; for 24.0h;	General procedure: To a solution of 2-methylquinolines 1 (0.3 mmol), amines 2 (0.6 mmol), intoluene (0.5 mL) was added La(Pfb)3 (0.015 mmol). After being stirred at 120 oC for24 h, the mixture was evaporated under vacuum. The corresponding products wereisolated by silica gel column chromatography with petroleum ether/ethyl acetatemixture as eluent.

Reference： [1]Synlett,2016,vol. 27,p. 2481 - 2484

43
[ 4965-34-8 ]
[ 165112-03-8 ]

Reference： [1]Journal of the American Chemical Society,2016,vol. 138,p. 13493 - 13496

44
4-(4-bromo-2-nitro-phenyl)-but-3-en-2-one [ No CAS ]
[ 4965-34-8 ]

Reference： [1]Organic and Biomolecular Chemistry,2017,vol. 15,p. 6349 - 6352

45
[ 70557-29-8 ]
[ 4965-34-8 ]

Reference： [1]Organic and Biomolecular Chemistry,2017,vol. 15,p. 6349 - 6352

46
[ 5551-12-2 ]
[ 4965-34-8 ]

Reference： [1]Organic and Biomolecular Chemistry,2017,vol. 15,p. 6349 - 6352

47
(E)-4-(2-amino-4-bromophenyl)but-3-en-2-one [ No CAS ]
[ 4965-34-8 ]

Reference： [1]Organic and Biomolecular Chemistry,2017,vol. 15,p. 6349 - 6352

48
[ 4965-34-8 ]
2-[(tert-butyldimethylsilyl)oxy]methyl}quinolin-7-amine [ No CAS ]

Reference： [1]ChemistryOpen,2017,vol. 6,p. 660 - 667

49
[ 4965-34-8 ]
[ 1315248-62-4 ]

Reference： [1]ChemistryOpen,2017,vol. 6,p. 660 - 667
[2]ChemistryOpen,2017,vol. 6,p. 660 - 667

50
[ 4965-34-8 ]
[ 1315248-35-1 ]

Reference： [1]ChemistryOpen,2017,vol. 6,p. 660 - 667
[2]ChemistryOpen,2017,vol. 6,p. 660 - 667

51
[ 4965-34-8 ]
[ 1315248-37-3 ]

Reference： [1]ChemistryOpen,2017,vol. 6,p. 660 - 667
[2]ChemistryOpen,2017,vol. 6,p. 660 - 667

52
[ 4965-34-8 ]
[ 768-56-9 ]
2-methyl-7-(1-phenylbutyl)quinoline [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2017,vol. 139,p. 13929 - 13935

53
[ 4965-34-8 ]
7-bromo-2-(iodomethyl)quinoline [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
77%	With copper(ll) sulfate pentahydrate; iodine; In acetonitrile; at 70℃; for 3.0h;	General procedure: 2-Methylazaarenes (0.5mmol), iodine (0.375mmol, 95.3mg), CuSO4·5H2O (0.2mmol, 50mg) and CH3CN (2mL) were stirred at 70C for 3h. Then, the reaction mixture was diluted by water and extracted with CH2Cl2 (3×15mL). The residue I2 in organic phase was quenched by Na2S2O3. The combined organic layers were washed with saturated NH4Cl aqueous solution and dried over anhydrous Na2SO4. After filtration, the solvent was evaporated in vacuo. The desired product was obtained by silica gel chromatography (petroleum ether/ethyl acetate, v/v=10/1).

Reference： [1]Tetrahedron,2018,vol. 74,p. 1908 - 1917

54
6-bromo-2,1-benzisoxazole [ No CAS ]
C₃H₅Zn⁽¹⁺⁾*C₅H₉O₂^(1-) [ No CAS ]
[ 4965-34-8 ]

Reference： [1]Journal of the American Chemical Society,2019,vol. 141,p. 98 - 103

55
[ 4965-34-8 ]
[ 373-52-4 ]
7-(fluoromethyl)-2-methylquinoline [ No CAS ]

Reference： [1]Chemical Communications,2019,vol. 55,p. 7635 - 7638

56
[ 4965-34-8 ]
[ 613-94-5 ]
2-(7-bromoquinolin-2-yl)-5-phenyl-1,3,4-oxadiazole [ No CAS ]

Reference： [1]New Journal of Chemistry,2019,vol. 43,p. 15999 - 16006

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 4965-34-8 ]

Bromides

[ 141052-31-5 ]

7-Bromo-4-methylquinoline

Similarity: 0.91

[ 700871-88-1 ]

4,7-Dibromoquinoline

Similarity: 0.91

[ 41037-28-9 ]

6-Bromo-4-methylquinoline

Similarity: 0.89

[ 57339-57-8 ]

6-Bromoquinolin-8-amine

Similarity: 0.89

[ 16567-18-3 ]

8-Bromoquinoline

Similarity: 0.89

Related Parent Nucleus of
[ 4965-34-8 ]

Quinolines

[ 141052-31-5 ]

7-Bromo-4-methylquinoline

Similarity: 0.91

[ 700871-88-1 ]

4,7-Dibromoquinoline

Similarity: 0.91

[ 41037-28-9 ]

6-Bromo-4-methylquinoline

Similarity: 0.89

[ 57339-57-8 ]

6-Bromoquinolin-8-amine

Similarity: 0.89

[ 16567-18-3 ]

8-Bromoquinoline

Similarity: 0.89

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 4965-34-8 ] {[proInfo.proName]}

Quality Control of [ 4965-34-8 ]

Related Doc. of [ 4965-34-8 ]

Product Details of [ 4965-34-8 ]

Calculated chemistry of [ 4965-34-8 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 4965-34-8 ]

Application In Synthesis of [ 4965-34-8 ]

[ 4965-34-8 ] Synthesis Path-Upstream 1~7

[ 4965-34-8 ] Synthesis Path-Downstream 1~56

Related Functional Groups of [ 4965-34-8 ]

Bromides

Related Parent Nucleus of [ 4965-34-8 ]

Quinolines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 4965-34-8 ]

Related Parent Nucleus of
[ 4965-34-8 ]